Cargando…
MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
Somatostatin receptor ligands (SRL) and GHR antagonists are used for persistent or recurrent acromegaly following noncurative surgery and as primary therapy for patients unsuitable for surgery. We tested in vitro action of a novel oral SRL compound ONO-5788 and its active metabolite (ONO-ST1-641) wh...
Autores principales: | Zhou, Cuiqi, Bonert, Vivien, Mamelak, Adam, Kelly, Daniel, Barkhoudarian, Garni, Hoon, Dave, Komagata, Tatsuya, Shinozaki, Koji, Melmed, Shlomo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551177/ http://dx.doi.org/10.1210/js.2019-MON-459 |
Ejemplares similares
-
MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey
por: Tanaka, Hirotaka, et al.
Publicado: (2019) -
MON-464 Non-Clinical Profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, to Support Studies in Humans
por: Komagata, Tatsuya, et al.
Publicado: (2019) -
THU045 WIP1 Phosphatase Is A Novel Specific Target For Epithelial GH Action
por: Apaydin, Tugce, et al.
Publicado: (2023) -
SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 Agonist
por: Kaviya, Arpeat, et al.
Publicado: (2019) -
GH Is a Component of SASP in Aging Tissue
por: Chesnokova, Vera M, et al.
Publicado: (2021)